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http://dx.doi.org/10.1016/j.asjsur.20Summary Inflammatory myofibroblastic tumors (IMTs) are rare soft-tissue tumors that can
occur at virtually any anatomical site. We report the case of a 58-year-old male with an IMT
of the fourth part of the duodenum who presented with signs and symptoms of high intestinal
obstruction and bilious vomiting. The patient underwent a surgical resection of the fourth part
of the duodenum with end-to-end duodenojejunal anastomosis. The follow-up period of
6 months was uneventful with no evidence of recurrence. According to our knowledge, only
six cases of duodenal IMTs have been reported in the literature thus far, and this is the first
report of a duodenal IMT sited at the fourth part of the duodenum. The duodenum is among
the rarest sites of IMTs. Signs and symptoms resulting from diagnostic imaging investigations
are nonspecific and inadequate to obtain diagnosis accurately. In most cases, surgical treat-
ment is considered a cure for IMTs. There is no evidence of deaths caused by duodenal IMT.
IMT of the duodenum is a possible diagnosis in differential diagnosis of tumor-like lesions of
the duodenum.
Copyright ª 2013, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Inflammatory myofibroblastic tumors (IMTs) are rare tumors
histologically composed of spindle myofibroblasts and annt of Internal Medicine,
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13.09.015inflammatory infiltrate dominated by plasma cells, lym-
phocytes, and eosinophils.1 According to the World Health
Organization, IMTs belong to a group of soft-tissue tumors,
a subset of fibroblastic/myofibroblastic tumors.2 These
principally occur in soft tissues and visceral organs at
possibly any anatomical location. Nevertheless, duodenal
IMTs remain an extremely rare condition. We report a case
of IMT of the fourth part of the duodenum. Only six cases ofyofibroblastic tumors of the duodenum, Asian Journal of Surgery
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+ MODELduodenal IMTs have been reported in literature thus far. We
present a review of these cases.3e8Figure 1 Contrast imaging of the small intestine displays the
narrowing of the ascending duodenum.
Figure 2 Multislice computed tomography demonstrates a
filling defect in the fourth part of the duodenum.2. Case report
A 58-year-old male who presented with a 1-week history of
an intermittent epigastric pain, bilious vomiting, and un-
intentional weight loss of 10 kg in 4 weeks was admitted to
the Department of Surgery of Clinical University Hospital
Center. His medical history was significant for gastro-
esophageal reflux disease (GERD), Helicobacter pylori
gastritis, Gilbert’s syndrome, and acute pancreatitis of
unknown exact cause 2 months ago, which was successfully
treated conservatively. Multiple abdominal ultrasonogra-
phies (USs) and multislice computed tomography (MSCT)
scans excluded cholelithiasis and there was no evidence of
alcohol abuse in the patient’s history (gamma glutamyl
transferase: 17 U/L). Other causes of acute pancreatitis
could neither be proven with certainty nor excluded.
A physical examination demonstrated abdominal bloat-
ing and visible distension with pain on palpation of the
epigastric area of the abdomen. There was no jaundice,
fever, or anemia. Laboratory tests revealed slightly
elevated levels of aspartate transaminase (46 U/L), alanine
transaminase (72 U/L), total bilirubin (58 mmol/L), and
direct bilirubin (10 mmol/L). Other laboratory examinations
analyzing the levels of C-reactive protein, erythrocyte
sedimentation rate, complete blood count, coagulation
factors, urea, creatinine, lipidogram, serum amylase,
electrolytes including calcium, phosphorus, and magnesium
were all within normal limits. Tumor markers such as cancer
antigen 19-9, alpha-fetoprotein, and cancer antigen 125
were all negative.
Abdominal X-ray, abdominal US, and esophagogas-
troduodenoscopy showed no significant findings. Contrast
imaging of the small intestine displayed a severe stricture
of the ascending duodenal portion (D4) measuring 0.8 cm in
diameter with normal duodenal mucosal folds and normal
morphology of the horizontal and descending portions of
the duodenum (Fig. 1).
The MSCT scan of the abdomen revealed a filling defect
in the fourth part of the duodenum measuring 4.3  3.6 cm2
and dilatation of the second and third part of the duo-
denum. Triangle-shaped infiltration area of the adipose
tissue measuring 2.1  1.9 cm2 was identified cranial to the
fourth part of the duodenum (Fig. 2). No regional lymph-
adenopathy or focal lesions of parenchymatous organs of
the abdomen suggestive of metastatic lesions were
identified.
Because imaging findings could not exclude malignancy
and the mass appeared to be resectable, a surgical explo-
ration was performed through an upper midline laparot-
omy. A firm, elastic tumor measuring 4 cm was found in the
fourth part of the duodenum, adjacent to the paraduodenal
adipose tissue and peritoneum surrounding the duodeno-
jejunal flexure. The head of the pancreas and the hep-
atoduodenal ligament were intact. After the right colon and
the mesenteric root mobilization, superior mesenteric ar-
tery 5 cm in length was exposed, and resection of the
duodenojejunal flexure measuring 15 cm in length with 2-
cm surgical resection margin and clearance of loco-regionalPlease cite this article in press as: Petrovic I, et al., Inflammatory m
(2013), http://dx.doi.org/10.1016/j.asjsur.2013.09.015lymph nodes were performed (Fig. 3). End-to-end duode-
nojejunal anastomosis with single-layer continuous suture
was made for reconstruction. Macroscopic pathology
demonstrated a segment of the duodenum 15.5 cm in
length and 3.2 cm in diameter with exophytic polypoid
tumor measuring 2.1  1.6 cm2 arising from the duodenal
wall (Fig. 4). Histologically, the tumor was composed of
spindle-shaped interspersed myofibroblasts separated with
fibrous stroma infiltrated by predominantly mononuclear
inflammatory cells (Figs. 5 and 6). The tumor cells were
immunohistochemically positive for actin, vimentin, AE1/
AE3, and negative for nonspecific esterase, CD34, CD117, S-
100, and DOG1. The resection margins were clear of ma-
lignancy. In the surrounding adipose tissue, seven lymph
nodes were found, which had a diameter from 0.4 to
1.2 cm, uninvolved with tumor tissue. A postoperativeyofibroblastic tumors of the duodenum, Asian Journal of Surgery
Figure 3 Surgical exploration of the tumor and the demon-
stration of the superior mesenteric artery.
Figure 5 Photomicrograph demonstrating an admixture of
spindle-shaped and ovoid cells with a prominent inflammatory
infiltrate (hematoxylineeosin; low-power view; magnification
10).
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tient’s symptoms. Six months after the surgery the patient
remained asymptomatic with no evidence of recurrence
detected by the MSCT scans.
3. Discussion
Different terms for IMT have been useddinflammatory
pseudotumor,9 fibrous xanthoma, plasma cell granuloma,10
pseudosarcoma, lymphoid hamartoma, myxoid hamar-
toma,11 inflammatory myofibrohistiocytic proliferation,
pseudosarcomatous myofibroblastic proliferation.12 The
term “inflammatory pseudotumor” has for many years been
used for any clinically, macroscopic, or microscopic tumor-
like lesion caused by inflammatory or reactive process.13
Later, the term has been applied only to neoplastic le-
sions microscopically characterized by the proliferation of
spindle cells of mesenchymal origin with morphological
characteristics of myofibroblasts and large inflammatoryFigure 4 Segment of the duodenum 15.5 cm in length and
3.2 cm in diameter with exophytic polypoid tumor measuring
2.1  1.6 cm arising from the duodenal wall.
Please cite this article in press as: Petrovic I, et al., Inflammatory m
(2013), http://dx.doi.org/10.1016/j.asjsur.2013.09.015infiltration of different types of cells, usually with pre-
dominance of mature lymphocytes and plasma cells,
regardless of etiology. However, during the last two de-
cades, due to a greater understanding of the importance of
myofibroblastic component in relation to inflammatory
component1,14 and additional electron microscopic and
immunohistochemical findings, this term has entirely
replaced other terms.15
IMTs occur mainly in children and young adults, with
more reports published on IMTs in adults recently.16,17
However, their etiology is unknown. Two basic hypothe-
ses, reactive and neoplastic, are complemented with pre-
sumably infectious and autoimmune hypotheses. However,
the exact infectious agents are not known. Some relate
IMTs to EpsteineBarr virus, human herpesvirus-8, the bac-
terium Eikenella corrodens, and schistosomiasis.18e21
Others claim that previous surgical manipulation andFigure 6 Photomicrograph showing a conspicuous admixture
of lymphocytes and plasma cells (high-power view; magnifi-
cation 40).
yofibroblastic tumors of the duodenum, Asian Journal of Surgery
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Some studies suggest the possible autoimmune origin of
IMTs.25 According to these hypotheses, a medical history of
acute pancreatitis, GERD, and H. pylori gastritis could be
contributing factors in our case.
Based on the anatomical site, IMTs can be pulmonary and
extrapulmonary.17 Extrapulmonary IMTs are most frequent
in the abdomen including the mesentery and omentum.16
Other sites of the gastrointestinal tract are all visceral or-
gans such as the appendix, Meckel’s diverticulum, and
Vater’s papilla.3,22,24,26,27 Duodenal IMTs are among the
rarest. To our knowledge, only six cases of duodenal IMTs
have been reported, five of which had anatomical sites at
the first and second parts of the duodenum, and one,
particularly interesting, multiple IMT arising from the first
part of the duodenum and extending up to the first part of
the jejunum.3e8 According to the available literature, our
patient is the first with IMT localization in the fourth part of
the duodenum (Table 13e8). Specific risk factors are not
defined and potential risk factors of duodenal IMT are
provided in Table 1. Considering these cases, there seemsTable 1 Review of duodenal IMT case reports and potential ris
Author Segment of
duodenum
Age (y)/
sex
Symptoms and
signs
Tr
Fong et al3 Second/third 57/F Gastric outlet
obstruction
W
Stringer et al4 Second 5/F Nonbilious
vomiting;
significant
weight loss
W
Mattei and
Barnaby5
First/second 13/M Asymptomatic
(incidentally
diagnosed IMT)
In
Wynn et al6 First 16/M Abdominal pain;
night sweats;
malaise
En
Mirshemirani
et al7
First 13/M Abdominal pain;
weight loss;
epigastric mass
Su
Xiang et al8 Multiple IMT
(from the
first part of
the duodenum
to starting
part of the
jejunum)
20/M Intermittent right
epigastric pain;
nausea;
vomiting
W
Current study Fourth 58/M Bilious vomiting;
epigastric pain;
significant
weight loss
Re
GERD Z gastroesophageal reflux disease; IMT Z inflammatory myofib
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(2013), http://dx.doi.org/10.1016/j.asjsur.2013.09.015to be no gender or age predilection (Table 1). Signs and
symptoms of abdominal IMTs often mimic malignant tu-
mors.22,28 Duodenal IMTs mostly present with upper
gastrointestinal-tract obstructive symptoms, nausea, vom-
iting, pain in the epigastric area, anorexia, weight loss,
malaise and fatigue, while in one of the cases night sweats
were referred to as one of the significant symptoms. None
of the cases presented with jaundice.3e8 Bilious vomiting,
present in our patient, was not described previously (Table
1).
Diagnostic imaging techniques demonstrate tumor mass
with its extent without specific features necessary for
obtaining accurate diagnosis. Stricture of the duodenum,
impossible passage, and irregular masses arising from
different parts of the duodenum are most usual findings on
radiological examination. It can be difficult to distinguish
duodenal IMT from other groups of soft-tissue tumors or
even pure (post)inflammatory strictures due to long-
standing ulcer or diverticulitis. Stenosis due to duodenal
ulcer can be divided into acute/active and chronic ulcera-
tion. Acute ulceration results in inflammatory edema andk factors.
eatment Recurrence
(treatment)
Potential risk
factors
hipple operation None No report
hipple operation
with standard
reconstruction
None None
travenous NSAID
application
(ketorolac);
laparotomy (tumor
mass regression)d
Roux-en-Y
gastrojejunostomy
None Paratesticular
rhabdomyosarcoma
-bloc excision
with primary
closure of the
duodenum
Yes (perioral
corticosteroids;
azathioprine)
No report
rgical resection
of the tumor;
duodeno
eduodenostomy
None No report
hipple operation None Calculous
colecystits
section of the
duodenojejunal
flexure with
termino-terminal
anastomosis
None Acute pancreatitis;
GERD; H. pylori
gastritis
roblastic tumor; NSAID Z nonsteroidal anti-inflammatory drug.
yofibroblastic tumors of the duodenum, Asian Journal of Surgery
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+ MODELpylorospasm. Signs and symptoms of stenosis may regress if
the ulcer heals under medical treatment, which is not
noticed in IMT cases. Long-standing ulceration can present
with radiological demonstration of scarring and deformities
of the duodenum. In most cases, there are no signs of
tumorous mass. Past medical history of peptic ulcer-type
pain for 10 or more years strongly suggests the precise
diagnosis29,30 contrary to duodenal diverticula, which are
the uncommon site of inflammation due to their large size
and mostly sterile content of the duodenum. The incidence
of duodenal diverticula is approximately 22% with the
incidence of complicated duodenal diverticulum estimated
from 0.03% to 5%. Inflammation of the diverticulum can be
distinguished before surgery by meticulous CT scan anal-
ysis. The CT findings vary between saccular and tubular
configuration, diverticular content (homogenous liquid,
liquid debris, and hydroaeric levels), wall (thickened,
enhanced, and thin), retroperitoneal infiltration, free air,
and signs of common bile duct dilatation.31,32
Definitive diagnosis of IMTs is confirmed by histopatho-
logical analysis and immunohistochemical tests of surgi-
cally removed specimen. Some histopathological IMT
patterns such as compact fascicular spindle cells with
myxoid or collagenized regions intermingled with inflam-
matory cells may resemble fibromatoses. Fibromatosis
colli, juvenile hyaline fibromatosis, superficial fibroma-
tosis, desmoid-type fibromatosis, and lipofibromatosis are
well-defined soft-tissue tumors histopathologically differ-
entiated from IMT. These benign neoplasms can extend into
adjacent tissues, and sometimes have a tendency toward
local recurrence, but do not metastasize. Except superfi-
cial fibromatosis and desmoid-type fibromatosis, other en-
tities of this group occur mostly in infants or early
childhood with no sex predilection. Superficial and
desmoid-type fibromatosis occur mostly in adults with
slight predominance in men of first entity and in women of
second entity. To the best of our knowledge and according
to available literature, no cases of fibromatoses of duo-
denum were reported so far.2
The basic principle for IMTs treatment is complete sur-
gical resection.16 In nonresectable tumors, a palliative
treatment regimen with radiotherapy and nonsteroidal
anti-inflammatory drugs (NSAIDs) can be applied. However,
guidelines for this treatment approach do not exist. Some
studies recommend the use of NSAIDs, corticosteroids, and
immunosuppressive drugs after the surgery. One case of the
duodenal IMT recurrence was successfully treated by the
application of NSAIDs and immunosuppressive drugs.5,6,33
IMTs are among the increasing number of diseases in
which aberrant anaplastic lymphoma kinase gene (ALK) has
been implicated in their pathogenesis.34 Considering ALK
expression in approximately 50% of IMTs, abrogation of ALK
signaling through direct kinase inhibition has become an
attractive therapeutic intervention point. So far, IMTs are
among particularly promising tumors for targeted therapy
using crizotinib, a small-molecule inhibitor.35
Surgical excision of the tumor is considered to cure IMTs;
however, due to its potential recurrence capability, a long-
term follow-up is recommended. Relapse predictors are not
known. Combination of atypia, ganglion-like cells, ALK
positivity, and aneuploidy suggests more aggressive poten-
tial. The main prognostic indicator is the adequacy of thePlease cite this article in press as: Petrovic I, et al., Inflammatory m
(2013), http://dx.doi.org/10.1016/j.asjsur.2013.09.015primary excision.2 According to available literature, there
are no general IMT survival statistics. These previous
studies are mainly related to low mortality rate due to IMT,
rare distant metastases, and rare recurrence of the dis-
ease. In Coffin’s review of 84 cases of extrapulmonary IMTs
after clinical follow-up in 53 cases, 44 had no evidence of
disease, four had IMT, and five died due to complications
related to the location of the lesion or the treatment of the
disease.17 Moreover, Coffin et al define IMT as a non-
metastasizing proliferation of myofibroblasts. Only a few
cases described in the literature specify IMT as a cause of
death, mostly due to the localization of the tumor (e.g.,
heart).36
A review of the treatment methods for duodenal IMTs is
provided in Table 1. There were no complications reported
during postoperative recovery. One patient developed a
recurrence 6 months after the surgery, which was suc-
cessfully treated by immunosuppressive drugs (Table 1).
During the follow-up of 2 months to 2 years, all patients
including ours, were alive with no evidence of recurrence.
According to these reports, IMT of the duodenum can be
considered as a tumor with good prognosis, low mortality
rate, and low recurrence potential.
In conclusion, the duodenum is among the rarest sites of
IMTs. Signs and symptoms as results of diagnostic imaging
investigations are nonspecific and inadequate to accurately
obtain diagnosis. The diagnosis can be confirmed only by a
histopathological analysis and immunohistochemical tests of
the surgically removed specimens. Inmost cases of duodenal
IMTs, surgical treatment is considered to cure the disease.
There is no evidence of deaths caused by duodenal IMTs. All
reported patients with duodenal IMTs had an uneventful re-
covery. Duodenal IMT should be considered in differential
diagnosis of tumor-like lesions of the duodenum.References
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